We have shown, for the first time, that pharmacological inhibition of IRAP via central administration of two distinct classes of small molecular weight IRAP inhibitors significantly improved morphological and functional outcomes following stroke in the SHR, even when treatment was delayed to 6 h post stroke. This evidence concerns the gene LNPEP and stroke disorder.